Literature DB >> 8853095

Liposomal bupivacaine. Extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient.

J J Mowat1, M J Mok, B A MacLeod, T D Madden.   

Abstract

BACKGROUND: There is a clinical requirement for longer-acting local anesthetics, particularly for the management of post-operative and chronic pain. In this regard, liposomes have been suggested to represent a potentially useful vehicle for sustained drug release after local administration. In the current study, the authors used a transmembrane pH gradient to efficiently encapsulate bupivacaine within large unilamellar vesicles. They report on the kinetics of drug uptake and release and the duration of nerve blockade.
METHODS: The rate and extent of bupivacaine uptake into large unilamellar vesicles that exhibit a pH gradient (interior acidic) were determined and compared to drug association with control liposomes that did not exhibit a proton gradient. In subsequent studies, researchers examined the kinetics of bupivacaine release from these liposome systems in vitro. Using the guinea pig cutaneous wheal model, the rate of clearance of the liposome carrier was monitored after intradermal administration, using a radiolabelled lipid marker, and the duration of nerve blockade produced by free and liposomal bupivacaine was compared.
RESULTS: Bupivacaine was rapidly and efficiently accumulated within liposomes that exhibited a pH gradient (interior acidic) with trapping efficiencies of 64-82% of total drug, depending on the initial bupivacaine:phospholipid ratio. Little uptake was seen, however, for control vesicles that did not exhibit a transmembrane proton gradient. Using an in vitro model of drug clearance, liposomally encapsulated bupivacaine was found to be slowly released for a longer period of time compared with either the free drug or bupivacaine associated with control (no pH gradient liposomes). In the guinea pig cutaneous wheal model, more than 85% of the liposomal carrier was found to remain at the site of administration for 2 days. The sustained drug release afforded by liposomes that exhibited a pH gradient resulted in an increase in the duration of nerve blockade of as much as threefold compared with either the free drug or bupivacaine in the presence of control (no pH gradient) liposomes. Recovery of half maximal response (R2.5) after administration of 0.75% free bupivacaine, for example, was approximately 2 h, whereas the same dose of bupivacaine in pH gradient liposomes exhibited a R2.5 of approximately 6.5 h.
CONCLUSIONS: Large unilamellar vesicles that exhibit a pH gradient can efficiently encapsulate bupivacaine and subsequently provide a sustained-release system that greatly increases the duration of neural blockade.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853095     DOI: 10.1097/00000542-199609000-00024

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

1.  DRV liposomal bupivacaine: preparation, characterization, and in vivo evaluation in mice.

Authors:  G J Grant; Y Barenholz; B Piskoun; M Bansinath; H Turndorf; E M Bolotin
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

Review 2.  The history and progress of local anesthesia: multiple approaches to elongate the action.

Authors:  Masaru Tobe; Takashi Suto; Shigeru Saito
Journal:  J Anesth       Date:  2018-05-31       Impact factor: 2.078

3.  Multivesicular liposomal bupivacaine at the sciatic nerve.

Authors:  J Brian McAlvin; Robert F Padera; Sahadev A Shankarappa; Gally Reznor; Albert H Kwon; Homer H Chiang; Jason Yang; Daniel S Kohane
Journal:  Biomaterials       Date:  2014-03-06       Impact factor: 12.479

4.  Inclusion Complex between Local Anesthetic/2-hydroxypropyl-β-cyclodextrin in Stealth Liposome.

Authors:  Gredson Keiff Souza; André Gallo; Luiza Hauser Novicki; Heitor Rodrigues Neto; Eneida de Paula; Anita Jocelyne Marsaioli; Luis Fernando Cabeça
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

Review 5.  [Liposomal bupivacaine-No breakthrough in postoperative pain management].

Authors:  Berit Otremba; Hanns-Christian Dinges; Ann-Kristin Schubert; Wolfgang Zink; Thorsten Steinfeldt; Hinnerk Wulf; Thomas Wiesmann
Journal:  Anaesthesiologie       Date:  2022-04-25

6.  Local myotoxicity from sustained release of bupivacaine from microparticles.

Authors:  Robert Padera; Evangelia Bellas; Julie Y Tse; Daphne Hao; Daniel S Kohane
Journal:  Anesthesiology       Date:  2008-05       Impact factor: 7.892

7.  Local toxicity from local anesthetic polymeric microparticles.

Authors:  J Brian McAlvin; Gally Reznor; Sahadev A Shankarappa; Cristina F Stefanescu; Daniel S Kohane
Journal:  Anesth Analg       Date:  2013-03-04       Impact factor: 5.108

8.  Sustained Release of Lidocaine from Solvent-Free Biodegradable Poly[(d,l)-Lactide-co-Glycolide] (PLGA): In Vitro and In Vivo Study.

Authors:  Yi-Chuan Kau; Chia-Chih Liao; Ying-Chi Chen; Shih-Jung Liu
Journal:  Materials (Basel)       Date:  2014-09-16       Impact factor: 3.623

9.  Liposomal bupivacaine: a review of a new bupivacaine formulation.

Authors:  Praveen Chahar; Kenneth C Cummings
Journal:  J Pain Res       Date:  2012-08-14       Impact factor: 3.133

10.  Encapsulation of ropivacaine in a combined (donor-acceptor, ionic-gradient) liposomal system promotes extended anesthesia time.

Authors:  Camila Morais Gonçalves da Silva; Michelle Franz-Montan; Cíntia Elisabeth Gomez Limia; Lígia Nunes de Morais Ribeiro; Mário Antônio Braga; Viviane Aparecida Guilherme; Camila Batista da Silva; Bruna Renata Casadei; Cíntia Maria Saia Cereda; Eneida de Paula
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.